Inozyme Pharma Shares Are Trading Higher After the Company Announced That It Will Discuss Topline Data From Its Ongoing Phase 1/2 Trial of INZ-701 in Adults With ABCC6 Deficiency, and From All Cohorts of Its Ongoing Phase 1/2 Trial of INZ-701 in Adults With ENPP1 Deficiency
Inozyme Pharma 的股價走高，此前該公司宣佈將討論其正在進行的針對 ABCC6 缺乏的成年人的 INZ-701 的 1/2 期試驗以及正在進行的 ENPP1 缺乏成人 INZ-701 的 1/2 期試驗的頭條數據